Evidence map›Paper›PMID 38467612›Full record

ArticleCell death & disease2024

A first-in-class TIMM44 blocker inhibits bladder cancer cell growth.

Lifeng Zhang, Xiaokai Shi, Lei Zhang, Yuanyuan Mi, Li Zuo, Shenglin Gao

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lifeng Zhang *Department of Urology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.ORCID 0009-0005-5634-5600
Xiaokai Shi *Department of Urology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
Lei Zhang *Department of Urology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
Yuanyuan MiDepartment of Urology, Affiliated Hospital of Jiangnan University, Wuxi, China.ORCID 0000-0003-3456-523X
Li ZuoDepartment of Urology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China. jiaomin0324@126.com.ORCID 0000-0002-3668-004X
Shenglin GaoDepartment of Urology, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China. gaoshenglin12135@njmu.edu.cn.
Changzhou No.2 People's Hospital · CNJiangnan University · CNQinghai Tibetan Hospital · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81902565
6 · The paper itself

Abstract

Mitochondria play a multifaceted role in supporting bladder cancer progression. Translocase of inner mitochondrial membrane 44 (TIMM44) is essential for maintaining function and integrity of mitochondria. We here tested the potential effect of MB-10 (MitoBloCK-10), a first-in-class TIMM44 blocker, against bladder cancer cells. TIMM44 mRNA and protein expression is significantly elevated in both human bladder cancer tissues and cells. In both patient-derived primary bladder cancer cells and immortalized (T24) cell line, MB-10 exerted potent anti-cancer activity and inhibited cell viability, proliferation and motility. The TIMM44 blocker induced apoptosis and cell cycle arrest in bladder cancer cells, but failed to provoke cytotoxicity in primary bladder epithelial cells. MB-10 disrupted mitochondrial functions in bladder cancer cells, causing mitochondrial depolarization, oxidative stress and ATP reduction. Whereas exogenously-added ATP and the antioxidant N-Acetyl Cysteine mitigated MB-10-induced cytotoxicity of bladder cancer cells. Genetic depletion of TIMM44 through CRISPR-Cas9 method also induced robust anti-bladder cancer cell activity and MB-10 had no effect in TIMM44-depleted cancer cells. Contrarily, ectopic overexpression of TIMM44 using a lentiviral construct augmented proliferation and motility of primary bladder cancer cells. TIMM44 is important for Akt-mammalian target of rapamycin (mTOR) activation. In primary bladder cancer cells, Akt-S6K1 phosphorylation was decreased by MB-10 treatment or TIMM44 depletion, but enhanced after ectopic TIMM44 overexpression. In vivo, intraperitoneal injection of MB-10 impeded bladder cancer xenograft growth in nude mice. Oxidative stress, ATP reduction, Akt-S6K1 inhibition and apoptosis were detected in MB-10-treated xenograft tissues. Moreover, genetic depletion of TIMM44 also arrested bladder cancer xenograft growth in nude mice, leading to oxidative stress, ATP reduction and Akt-S6K1 inhibition in xenograft tissues. Together, targeting overexpressed TIMM44 by MB-10 significantly inhibits bladder cancer cell growth in vitro and in vivo.

Indexed as

Signal TransductionUrinary Bladder NeoplasmsAdenosine TriphosphateAnimalsApoptosisCell Line, TumorCell ProliferationHumansMammalsMiceMice, NudeMitochondrial Precursor Protein Import Complex ProteinsProto-Oncogene Proteins c-aktUrinary BladderAdenosine TriphosphateMitochondrial Precursor Protein Import Complex ProteinsProto-Oncogene Proteins c-aktTIMM44 protein, human

Identifiers

PMID38467612
PMCPMC10928220
OpenAlexW4392659884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.